Recruitment of high risk women for HIV prevention trials: Baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial

Trials

Volumn 12, Issue , 2011, Pages

  Karim, Quarraisha A ^a,b   Kharsany, Ayesha B M ^a   Frohlich, Janet A ^a   Baxter, Cheryl ^a   Yende, Nonhlanhla ^a   Mansoor, Leila E ^a   Mlisana, Koleka P ^a   Maarschalk, Silvia ^a   Arulappan, Natasha ^a   Grobler, Anneke ^a   Sibeko, Sengeziwe ^a   Omar, Zaheen ^a   Gengiah, Tanuja N ^a   Mlotshwa, Mukelisiwe ^a   Samsunder, Natasha ^a   Abdool Karim, Salim S ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYETHYLCELLULOSE; PLACEBO; TENOFOVIR; VIRUS RNA; ADENINE; AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONDOM; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GEL; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT PARTICIPATION; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SOUTH AFRICA; URBAN RURAL DIFFERENCE; WOMEN'S HEALTH; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; PATIENT SELECTION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; RURAL POPULATION; SEX DIFFERENCE; TREATMENT OUTCOME; URBAN POPULATION;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; PATIENT SELECTION; PHOSPHONIC ACIDS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; RURAL POPULATION; SEX FACTORS; SEXUAL BEHAVIOR; SOUTH AFRICA; TREATMENT OUTCOME; URBAN POPULATION; VAGINAL CREAMS, FOAMS, AND JELLIES; WOMEN'S HEALTH; YOUNG ADULT;

EID: 79953030109     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-67     Document Type: Article

References (29)

1. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009, 374:921-933. 10.1016/S0140-6736(09)60916-8, 2803032, 19709731.
2. UNAIDS World Health Organization AIDS epidemic update: November 2009. 2009, "UNAIDS/09.36E/JC1700E". ISBN 978 92 9173 832 8 (NLM classification: WC 503.41), UNAIDS World Health Organization.
3. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-Madikizela L, et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 2005, 19:1525-1534. 10.1097/01.aids.0000183129.16830.06, 16135907.
4. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: A turning tide among teenagers?. 2009, Cape Town: HSRC Press.
5. Barnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell ML. High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study. AIDS 2008, 22:139-144. 10.1097/QAD.0b013e3282f2ef43, 18090402.
6. Pettifor A, Macphail C, Rees H, Cohen M. HIV and sexual behavior among young people: the South African paradox. Sex Transm Dis 2008, 35:843-844. 10.1097/OLQ.0b013e31818318c0, 18716569.
7. Cowan F, Pettifor A. HIV in adolescents in sub-Saharan Africa. Curr Opin HIV AIDS 2009, 4:288-293. 10.1097/COH.0b013e32832c7d10, 19532066.
8. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005, 308:1582-1583. 10.1126/science.1112489, 15947174.
9. Frohlich JA, Kharsany ABM, Carrara H, Makhaye GM, Abdool Karim SS, Abdool Karim Q. Temporal Trends in HIV infection in Rural South Africa: Implications for HIV Prevention Research. XV INTERNATIONAL AIDS CONFERENCE BANGKOK 11-16 JULY 2004 Abstract number MoPpC2013 2004,
10. Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, et al. The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr 2008, 47:93-100. 10.1097/QAI.0b013e31815c71f7, 17984760.
11. Abdool Karim Q, Kharsany A, Frohlich J, Werner L, Mashego M, Mlotshwa M, et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. International Journal of Epidemiology 2010,
12. Collins C, Coates TJ, Curran J. Moving beyond the alphabet soup of HIV prevention. AIDS 2008, 22(Suppl 2):S5-8. 10.1097/01.aids.0000327431.82795.49, 2873858, 18641471.
13. Padian NS, Buve A, Balkus J, Serwadda D, Cates W. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008, 372:585-599. 10.1016/S0140-6736(08)60885-5, 18687456.
14. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372:669-684. 10.1016/S0140-6736(08)60886-7, 2702246, 18687459.
15. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008, 3:e1474. 10.1371/journal.pone.0001474, 2190795, 18213382.
16. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007, 2:e1312. 10.1371/journal.pone.0001312, 2129116, 18091987.
17. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1977-1987. 10.1016/S0140-6736(08)61842-5, 19059048.
18. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008, 359:463-472. 10.1056/NEJMoa0707957, 18669425.
19. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977. 10.1016/S0140-6736(02)11079-8, 12383665.
20. Abdool Karim S, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, et al. Safety and effectiveness of vaginal microbicides buffer gel and 0.5% PRO 2000/5 gel for the prevention of HIV Infection in women: results of the HPTN 035 trial. 2009, Montreal, Canada, Oral Abstract 48LB, 16th Conference on Retroviruses and Opportunistic Infections.
21. IOM (Institute of Medicine) Methodological challenges in biomedical HIV prevention trials. 2008, Washington, DC: The National Academies Press, IOM (Institute of Medicine).
22. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. 10.1126/science.1193748, 20643915.
23. MacQueen KM, Karim QA. Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care 2007, 18:78-82. 10.1016/j.jana.2007.01.002, 2062499, 17403499.
24. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
25. Kharsany AB, Hancock N, Frohlich JA, Humphries HR, Abdool Karim SS, Abdool Karim Q. Screening for 'window-period' acute HIV infection among pregnant women in rural South Africa. HIV Med 2010, 11:661-665. 10.1111/j.1468-1293.2010.00838.x, 20497252.
26. Abdool Karim Q, Kharsany ABM, Naidoo K, Yende N, Gengiah T, Omar Z, et al. Co-enrollment in multiple HIV prevention trials: Experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials 2011,
27. International Conference on Harmonisation guidelines E9 International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartate guideline statistical principles for clinical trials-E9. 1998, International Conference on Harmonisation guidelines E9.
28. Welz T, Hosegood V, Jaffar S, Batzing-Feigenbaum J, Herbst K, Newell ML. Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS 2007, 21:1467-1472. 10.1097/QAD.0b013e3280ef6af2, 17589193.
29. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray CM, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008, 3:e1954. 10.1371/journal.pone.0001954, 2278382, 18414658.